rAAV2tYF-GRK1-RPGR

Gene therapy

BBeacon Therapeutics

rAAV2tYF-GRK1-RPGR is one of 30 biologic programs targeting Retinitis Pigmentosa. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Retinitis PigmentosaActive, not recruiting

Retinitis PigmentosaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

73 competitors in Retinitis Pigmentosa

#DrugCompanyPhaseTrials

Cysteine Hydrochloride

Novartis

Phase 3

1 2

Aquasol a

BBandim Health Project

Phase 3

2 3

Minocin

TTriax

Phase 3

2 4

Aquasol E

NNational Eye Institute (NEI)

Phase 3

1 5

Depakote

AbbVie

Phase 2

2 6

Eylea

Regeneron

Phase 2

1 7

Alphagan

AbbVie

Phase 2

1 8

Lutein

NNational Eye Institute (NEI)

Phase 3

2 9

Levodopa-Carbidopa

AbbVie

Phase 2

1 10

N-Acetylcysteine Amide

NNacuity Pharmaceuticals, Inc.

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Active, not recruiting

Retinitis Pigmentosa

NCT06333249

Clinical

Trials by Indication[1]

Retinitis Pigmentosa2 trials

Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations

Active, not recruiting·BBeacon Therapeutics·Phase 1/2·NCT03316560·29 enrolled

A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)

Active, not recruiting·BBeacon Therapeutics·Phase 2·NCT06333249·14 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for rAAV2tYF-GRK1-RPGR. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — rAAV2tYF-GRK1-RPGR compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for rAAV2tYF-GRK1-RPGR. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beacon Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Gene therapy[2]
Company: BBeacon Therapeutics

rAAV2tYF-GRK1-RPGR

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Retinitis Pigmentosa2 trials

References

Drug Info

Quick Facts

Related News